NYSE:QGEN - Qiagen Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Qiagen NV Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $41.81 +0.03 (+0.07 %) (As of 12/6/2019 04:00 PM ET) Add Compare Today's Range$41.73Now: $41.81▼$42.2850-Day Range$27.54MA: $34.89▼$42.9752-Week Range$25.04Now: $41.81▼$43.16Volume1.08 million shsAverage Volume1.46 million shsMarket Capitalization$9.43 billionP/E Ratio31.20Dividend YieldN/ABeta0.97 ProfileAnalyst RatingsAdvanced ChartEarningsFinancialsInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email QIAGEN N.V. provides sample to insight solutions that transform biological materials into molecular insights worldwide. The company offers sample technologies for plasmid deoxyribonucleic acid (DNA) purification, ribonucleic acid purification and stabilization, genomic and viral nucleic acid purification, DNA cleanup after polymerase chain reaction (PCR) and sequencing, target enrichment, and library preparation for sequencing applications; and assay technology solutions. Read More… Industry, Sector and Symbol Stock Exchange NYSE Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNYSE:QGEN Previous Symbol CUSIPN/A CIK1015820 Webhttp://www.qiagen.com/ Phone31-77-355-6600Debt Debt-to-Equity Ratio0.68 Current Ratio2.45 Quick Ratio2.18Price-To-Earnings Trailing P/E Ratio31.20 Forward P/E Ratio29.86 P/E Growth3.2 Sales & Book Value Annual Sales$1.50 billion Price / Sales6.28 Cash Flow$2.40 per share Price / Cash Flow17.43 Book Value$11.69 per share Price / Book3.58Profitability EPS (Most Recent Fiscal Year)$1.34 Net Income$190.38 million Net Margins-1.68% Return on Equity12.24% Return on Assets5.83%Miscellaneous Employees4,952 Outstanding Shares225,509,000Market Cap$9.43 billion Next Earnings Date2/3/2020 (Estimated) OptionableOptionable Receive QGEN News and Ratings via Email Sign-up to receive the latest news and ratings for QGEN and its competitors with MarketBeat's FREE daily newsletter. QGEN Rates by TradingView Qiagen (NYSE:QGEN) Frequently Asked Questions What is Qiagen's stock symbol? Qiagen trades on the New York Stock Exchange (NYSE) under the ticker symbol "QGEN." How were Qiagen's earnings last quarter? Qiagen NV (NYSE:QGEN) released its earnings results on Wednesday, October, 30th. The company reported $0.36 earnings per share for the quarter, beating the consensus estimate of $0.35 by $0.01. The firm had revenue of $382.70 million for the quarter, compared to analyst estimates of $382.98 million. Qiagen had a positive return on equity of 12.24% and a negative net margin of 1.68%. The company's quarterly revenue was up 1.3% on a year-over-year basis. During the same quarter in the prior year, the firm posted $0.35 earnings per share. View Qiagen's Earnings History. When is Qiagen's next earnings date? Qiagen is scheduled to release their next quarterly earnings announcement on Monday, February 3rd 2020. View Earnings Estimates for Qiagen. What guidance has Qiagen issued on next quarter's earnings? Qiagen issued an update on its FY19 earnings guidance on Wednesday, October, 30th. The company provided earnings per share (EPS) guidance of $1.43-1.44 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $1.38. The company issued revenue guidance of ~$1.56 billion, compared to the consensus revenue estimate of $1.53 billion. What price target have analysts set for QGEN? 17 Wall Street analysts have issued 1-year price targets for Qiagen's shares. Their forecasts range from $31.00 to $48.00. On average, they expect Qiagen's share price to reach $37.38 in the next twelve months. This suggests that the stock has a possible downside of 10.6%. View Analyst Price Targets for Qiagen. What is the consensus analysts' recommendation for Qiagen? 17 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Qiagen in the last year. There are currently 8 hold ratings and 9 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Qiagen. Has Qiagen been receiving favorable news coverage? Headlines about QGEN stock have been trending somewhat negative this week, according to InfoTrie. The research group rates the sentiment of media coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Qiagen earned a media sentiment score of -1.4 on InfoTrie's scale. They also gave media coverage about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the stock's share price in the next several days. View News Stories for Qiagen. Are investors shorting Qiagen? Qiagen saw a increase in short interest in October. As of October 15th, there was short interest totalling 4,010,000 shares, an increase of 13.3% from the September 15th total of 3,540,000 shares. Based on an average daily trading volume, of 1,390,000 shares, the days-to-cover ratio is currently 2.9 days. Approximately 1.9% of the shares of the stock are short sold. View Qiagen's Current Options Chain. Who are some of Qiagen's key competitors? Some companies that are related to Qiagen include Seattle Genetics (SGEN), NOVOZYMES A/S/S (NVZMY), Neurocrine Biosciences (NBIX), BIO-TECHNE (TECH), Moderna (MRNA), argenx (ARGX), BioNTech (BNTX), China Biologic Products (CBPO), Repligen (RGEN), bluebird bio (BLUE), Spark Therapeutics (ONCE), Crispr Therapeutics (CRSP), Ablynx (ABLYF), Adaptive Biotechnologies (ADPT) and Allogene Therapeutics (ALLO). What other stocks do shareholders of Qiagen own? Based on aggregate information from My MarketBeat watchlists, some companies that other Qiagen investors own include Netflix (NFLX), Gilead Sciences (GILD), NVIDIA (NVDA), Boeing (BA), Twitter (TWTR), Cisco Systems (CSCO), Exelixis (EXEL), QUALCOMM (QCOM), Activision Blizzard (ATVI) and Starbucks (SBUX). Who are Qiagen's key executives? Qiagen's management team includes the folowing people: Mr. Peer Michael Schatz, CEO, MD & Member of Management Board (Age 53)Dr. Roland Sackers, CFO, MD & Member of Management Board (Age 50)Dr. Barthold Piening, Sr. VP & Head of Global Operations (Age 61)Mr. John Gilardi, VP of Corp. Communications & Investor RelationsMr. Jean-Pascal Viola, Head of Corp. Bus. Devel., Intellectual Property & Litigation and Sr. VP Who are Qiagen's major shareholders? Qiagen's stock is owned by a variety of of institutional and retail investors. Top institutional investors include Massachusetts Financial Services Co. MA (5.55%), Hardman Johnston Global Advisors LLC (1.77%), State Street Corp (0.96%), First Trust Advisors LP (0.68%), Sycomore Asset Management (0.63%) and Parametric Portfolio Associates LLC (0.43%). Which institutional investors are selling Qiagen stock? QGEN stock was sold by a variety of institutional investors in the last quarter, including First Trust Advisors LP, Assenagon Asset Management S.A., Hardman Johnston Global Advisors LLC, Parametric Portfolio Associates LLC, Man Group plc, Exane Asset Management, Zurcher Kantonalbank Zurich Cantonalbank and Squarepoint Ops LLC. Which institutional investors are buying Qiagen stock? QGEN stock was bought by a variety of institutional investors in the last quarter, including Sycomore Asset Management, Massachusetts Financial Services Co. MA, Phoenix Holdings Ltd., Point72 Asset Management L.P., Fisher Asset Management LLC, SG Americas Securities LLC, Sector Gamma AS and Russell Investments Group Ltd.. How do I buy shares of Qiagen? Shares of QGEN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab. What is Qiagen's stock price today? One share of QGEN stock can currently be purchased for approximately $41.81. How big of a company is Qiagen? Qiagen has a market capitalization of $9.43 billion and generates $1.50 billion in revenue each year. The company earns $190.38 million in net income (profit) each year or $1.34 on an earnings per share basis. Qiagen employs 4,952 workers across the globe.View Additional Information About Qiagen. What is Qiagen's official website? The official website for Qiagen is http://www.qiagen.com/. How can I contact Qiagen? Qiagen's mailing address is HULSTERWEG 82, VENLO P7, 5912 PL. The company can be reached via phone at 31-77-355-6600 or via email at [email protected] MarketBeat Community Rating for Qiagen (NYSE QGEN)Community Ranking: 2.3 out of 5 ( )Outperform Votes: 193 (Vote Outperform)Underperform Votes: 218 (Vote Underperform)Total Votes: 411MarketBeat's community ratings are surveys of what our community members think about Qiagen and other stocks. Vote "Outperform" if you believe QGEN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe QGEN will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 12/6/2019 by MarketBeat.com StaffFeatured Article: Monthly Dividend Stocks Can Provide Solid Income